Novo Nordisk Property, Plant, and Equipment 2010-2024 | NVO

Novo Nordisk property, plant, and equipment from 2010 to 2024. Property, plant, and equipment can be defined as the sum of all net property, plant & Equipment fields. Where companies do not report a break down of plant, property, & equipment, the value is entered in this field alone.
  • Novo Nordisk property, plant, and equipment for the quarter ending September 30, 2024 was $17.663B, a 48.51% increase year-over-year.
  • Novo Nordisk property, plant, and equipment for 2023 was $13.208B, a 39.9% increase from 2022.
  • Novo Nordisk property, plant, and equipment for 2022 was $9.441B, a 7.18% increase from 2021.
  • Novo Nordisk property, plant, and equipment for 2021 was $8.808B, a 14.37% increase from 2020.
Novo Nordisk Annual Property, Plant, and Equipment
(Millions of US $)
2023 $13,208
2022 $9,441
2021 $8,808
2020 $7,701
2019 $7,578
2018 $6,405
2017 $5,354
2016 $4,485
2015 $3,801
2014 $4,125
2013 $3,897
2012 $3,722
2011 $3,912
2010 $3,656
2009 $3,601
Novo Nordisk Quarterly Property, Plant, and Equipment
(Millions of US $)
2024-09-30 $17,663
2024-06-30 $15,870
2024-03-31 $14,302
2023-12-31 $13,208
2023-09-30 $11,893
2023-06-30 $10,961
2023-03-31 $10,089
2022-12-31 $9,441
2022-09-30 $8,611
2022-06-30 $8,517
2022-03-31 $8,505
2021-12-31 $8,808
2021-09-30 $8,384
2021-06-30 $8,442
2021-03-31 $8,337
2020-12-31 $7,701
2020-09-30 $7,838
2020-06-30 $7,459
2020-03-31 $7,512
2019-12-31 $7,578
2019-09-30 $7,495
2019-06-30 $7,260
2019-03-31 $7,207
2018-12-31 $6,405
2018-09-30 $6,171
2018-06-30 $6,079
2018-03-31 $5,966
2017-12-31 $5,354
2017-09-30 $5,234
2017-06-30 $4,716
2017-03-31 $4,459
2016-12-31 $4,485
2016-09-30 $4,233
2016-06-30 $4,120
2016-03-31 $3,825
2015-12-31 $3,801
2015-09-30 $3,575
2015-06-30 $3,502
2015-03-31 $3,557
2014-12-31 $4,125
2014-09-30 $4,025
2014-06-30 $4,074
2014-03-31 $4,024
2013-12-31 $3,897
2013-09-30 $3,884
2013-06-30 $3,811
2013-03-31 $3,868
2012-12-31 $3,722
2012-09-30 $3,584
2012-06-30 $3,643
2012-03-31 $3,655
2011-12-31
2011-09-30
2011-06-30
2011-03-31
2010-12-31
2010-09-30
2010-06-30
2010-03-31
2009-12-31
2009-09-30
2009-06-30
2009-03-31
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $481.063B $33.708B
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $789.394B 81.76
Johnson & Johnson (JNJ) United States $374.313B 15.18
AbbVie (ABBV) United States $352.544B 18.56
Merck (MRK) United States $260.350B 17.30
Novartis AG (NVS) Switzerland $217.584B 14.46
AstraZeneca (AZN) United Kingdom $199.957B 17.81
Pfizer (PFE) United States $151.422B 10.36
Sanofi (SNY) $130.241B 11.80
Innoviva (INVA) United States $1.263B 10.51